Scenic Bio raises $31m for genetic modifier platform
pharmaphorum
MARCH 10, 2022
18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round financing that it will use to take its own genetic modifier-targeted medicines into clinical trials. The post Scenic Bio raises $31m for genetic modifier platform appeared first on.
Let's personalize your content